CONFIDENTIALTREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION MASTER PRECLINICAL STUDY AGREEMENTMaster Preclinical Study Agreement • March 30th, 2015 • MultiVir Inc. • Pharmaceutical preparations • Texas
This MASTER PRECLINICAL STUDY AGREEMENT (this “Master Agreement”) is effective March 6, 2008,(the “Effective Date”), between Introgen Therapeutics, Inc. (“Introgen”), and The University of Texas M. D. Anderson Cancer Center (“Institution”), a member institution of The University of Texas System (“System”). Based upon the Background below and in consideration of the mutual promises herein and the benefits hereunder, the parties agree as follows:
